Date: 2017-02-23
Type of information: Distribution agreement
Compound: SelectMDx™ for Prostate Cancer test
Company: MDxHealth (Belgium) Istituto Diagnostico Varelli (Italy)
Therapeutic area: Cancer - Oncology - Diagnostic
Type agreement: distribution
Action mechanism: biomarker/diagnostic test. The novel biomarkers that make up SelectMDx were discovered by Prof. Dr. Jack Schalken, original developer of the PCA3 assay, and his team at the Department of Urology at Radboud University Medical Center in the Netherlands. The SelectMDx test was designed to address an unmet need in the stratification of patients at risk for potentially lethal high-grade prostate cancer compared to those with low-grade cancer. In clinical studies, SelectMDx has been shown to outperform PCA3, improving the information available to urologists seeking to further reduce unnecessary invasive biopsy procedures.
Disease: prostate cancer
Details: * On February 23, 2017, MDxHealth announced that it has signed a distribution agreement to make its SelectMDx™ for Prostate Cancer test available to Istituto Diagnostico Varelli's urology clients throughout central-south Italy. Under the terms of the agreement, Istituto Diagnostico Varelli will serve as a non-exclusive distributor in Italy encompassing five of the country's 20 regions; Lazio, Apulia, Campania, Calabria and Basilicata. Liquid biopsy samples will be sent to MDxHealth's state-of-the-art clinical diagnostic laboratory in Nijmegen, The Netherlands for analysis. Istituto Diagnostico Varelli will reimburse MDxHealth for all testing services performed.
Financial terms:
Latest news:
